Core Viewpoint - Revvity, Inc. (RVTY) is expected to report its first-quarter 2025 results on April 28, with a consensus estimate for revenues at $662.2 million, reflecting a 1.9% increase year-over-year, while earnings per share (EPS) is projected at 96 cents, indicating a 2% decline year-over-year [1][2]. Q1 Estimates - The Zacks Consensus Estimate for revenues is $662.2 million, up 1.9% from the prior-year quarter [1] - The consensus mark for earnings is 96 cents per share, indicating a deterioration of 2% year-over-year [1] - Organic top-line growth is expected to be 3-5% in Q1, with 19% of full-year adjusted EPS guidance of $4.90-$5.00 anticipated in this quarter [2] Diagnostics Segment - The Diagnostics segment sales improved 6% organically in the fourth quarter, with strong performance expected to continue in Q1, driven by growth in Immunodiagnostics and Reproductive Health [3] - Immunodiagnostics is projected to grow in high-single digits, supported by strong commercial execution [3] - The estimated revenue for the Diagnostics segment is $324.8 million, down 6.4% year-over-year [6] Life Sciences Segment - The Life Sciences business improved 5% organically in the last reported quarter, primarily driven by recovery in pharma/biotech customer activity [7] - The estimated revenue for the Life Sciences segment is $338 million, up 11.6% year-over-year [8] - New offerings, Signals Clinical and Signals Synergy, are likely to drive adoption of Signals software during Q1 [7] Other Factors to Consider - Revvity announced an expansion of its work with Genomics England to advance genomic initiatives, which may boost newborn screening [9] - The launch of the TotalSeq Phenocyte single-cell protein profiling solution in collaboration with Scale Biosciences may have contributed additional revenues for the Life Sciences segment [10] - The company generates a portion of its sales from China, which is a crucial growth factor for its business in Asia [11] Earnings Beat Likely - The model predicts an earnings beat for Revvity, with an Earnings ESP of +0.52% [12]

Core Viewpoint - The market anticipates Revvity (RVTY) to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Revvity is expected to post quarterly earnings of $0.96 per share, reflecting a -2% change year-over-year, while revenues are projected to be $662.71 million, up 2% from the previous year [3]. - The consensus EPS estimate has been revised 0.13% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading indicates a likely earnings beat, particularly when combined with a strong Zacks Rank [8]. - For Revvity, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.52%, but the stock holds a Zacks Rank of 4, complicating predictions of an earnings beat [10][11]. Historical Performance - Revvity has a history of beating consensus EPS estimates, having done so in the last four quarters, including a +4.41% surprise in the most recent quarter [12][13]. Conclusion - While Revvity does not appear to be a strong candidate for an earnings beat, investors should consider other factors influencing stock performance ahead of the earnings release [16].

Revenue and Financial Performance - Revenue for fiscal year 2024 was $2,755.0 million, an increase of $4.5 million, or less than 1%, compared to fiscal year 2023[146]. - Diagnostics segment revenue increased by $42.7 million, or 3%, to $1,500.9 million, driven by growth in immunodiagnostics and reproductive health[157]. - Life Sciences segment revenue decreased by $38.2 million, or 3%, to $1,254.1 million, primarily due to a decline in instruments and reagents revenue[154]. - Total revenue for the year ended December 29, 2024, was $2.755 billion, a slight increase from $2.751 billion in 2023[220]. - Product revenue decreased to $2.338 billion in 2024 from $2.416 billion in 2023, while service revenue increased to $416.8 million from $334.7 million[220]. - Operating income from continuing operations rose to $346.7 million in 2024, compared to $300.6 million in 2023, reflecting a 15.4% increase[220]. - Net income for 2024 was $270.4 million, a significant decrease from $693.1 million in 2023, primarily due to losses from discontinued operations[220]. - Basic earnings per share from continuing operations increased to $2.31 in 2024 from $1.44 in 2023[220]. Expenses and Margins - Consolidated gross margin decreased by 16 basis points to 55.8% in fiscal year 2024, attributed to an unfavorable product mix and higher product costs[147]. - Consolidated operating margin increased by 166 basis points to 16.5% in fiscal year 2024, supported by productivity initiatives and cost containment[144]. - Research and development expenses decreased by $19.7 million, or 9%, to $196.8 million, representing 7.1% of revenue[149]. - Selling, general and administrative expenses decreased by $28.5 million, or 3%, to $994.1 million, accounting for 36.1% of revenue[148]. Cash Flow and Financing Activities - Net cash provided by continuing operations increased to $665.0 million in fiscal year 2024, up from $279.4 million in fiscal year 2023, reflecting higher income and less cash used for working capital[165]. - The company reported net cash used in financing activities of $1,128.2 million for fiscal year 2024, an increase of $181.1 million compared to $947.1 million in fiscal year 2023[168]. - The company authorized a new stock repurchase program for up to $1.0 billion, replacing the previous program, with $857.2 million remaining available for repurchases as of December 29, 2024[175]. - The company received cash proceeds of $2.27 billion from divestitures, with an additional $75 million expected from the Brand Sale and up to $150 million contingent on future sales by the Purchaser[181]. Tax and Interest Expenses - The effective tax rate for fiscal year 2024 was 10.5%, compared to 1.9% in fiscal year 2023[151]. - Interest and other expense, net, decreased significantly from $117.6 million in fiscal year 2023 to $30.6 million in fiscal year 2024[150]. - The total provision for income taxes for continuing operations was $33.1 million in 2024, compared to $3.5 million in 2023[295]. Assets and Liabilities - As of December 29, 2024, the company had cash and cash equivalents of $1,163.4 million, with $1.5 billion of borrowing capacity available under its senior unsecured revolving credit facility[173]. - Total assets decreased to $12.392 billion in 2024 from $13.565 billion in 2023[226]. - Total stockholders' equity decreased to $7.667 billion in 2024 from $7.873 billion in 2023[226]. - The company’s total liabilities decreased from $4,951,018 thousand in 2023 to $5,609,212 thousand in 2024[230]. Goodwill and Intangible Assets - The company's goodwill balance as of December 29, 2024, was $6.5 billion, with $4.3 billion allocated to the Life Sciences reporting unit[214]. - The fair value of the Life Sciences reporting unit exceeded its carrying value by more than 10% but less than 20% as of November 1, 2024[215]. - Total amortization expense related to amortizable intangible assets was $359.4 million in fiscal year 2024, with estimated future amortization expenses projected to decrease over the next five years[317]. Strategic Initiatives and Future Outlook - The company anticipates an increase in capital expenditures in fiscal year 2025, focusing on enhancing digital capabilities and product innovations[172]. - The company plans to fund its strategic initiatives through a combination of existing cash reserves and internally generated funds from continuing operations[172]. - The company expects to recognize substantially all deferred revenue within 12 months of the balance sheet date[287]. Discontinued Operations - For fiscal year 2024, the company recognized a loss of $12.7 million from discontinued operations, compared to income of $513.6 million in fiscal year 2023[162]. - The operating loss from discontinued operations for the fiscal year ended December 29, 2024, was $37.9 million, compared to an operating income of $68.4 million in 2023[292]. Pension and Benefit Obligations - The company recognized a net periodic pension cost of $10,314,000 for fiscal year 2024, compared to $20,062,000 in 2023[329]. - Accumulated benefit obligations for Non-U.S. increased to $212,120, while U.S. obligations rose to $90,293 as of December 29, 2024[332]. - The discount rate for Non-U.S. plans was 4.19% and for U.S. plans was 5.71% as of year-end measurement[332].

Core Viewpoint - Revvity, Inc. reported strong fourth-quarter 2024 results with adjusted EPS of $1.42, exceeding estimates and showing a year-over-year improvement of 13.6% [1][2] Financial Performance - GAAP EPS from continuing operations was 78 cents, up from 64 cents in the prior year, including 5 cents from discontinued operations [2] - Total revenues reached $729.3 million, reflecting a 4.8% year-over-year increase, but slightly missing the Zacks Consensus Estimate by 0.1% [3] Segment Analysis - Life Sciences segment revenues were $336 million, up 5% year-over-year, with adjusted operating income of $131 million, an 11% increase [4] - Diagnostics segment revenues totaled $393 million, a 4.5% year-over-year increase, with organic growth of 6% [4] Margin and Expense Analysis - Selling, general and administrative expenses decreased by 4.8% to $244.3 million, while research and development expenses were $49.2 million, down 0.8% [6] - Adjusted operating income improved by 15.4% to $221.3 million, with an adjusted operating margin of 28.3%, expanding by 280 basis points [6] Cash Flow and Financial Position - The company ended Q4 2024 with cash and cash equivalents of $1.16 billion, down from $1.23 billion in the previous quarter [7] - Net cash provided by operating activities was $174.2 million, compared to a net cash used of $196.6 million in the year-ago quarter [7] 2025 Guidance - For 2025, Revvity expects adjusted EPS in the range of $4.90-$5.00 and revenues between $2.80-$2.85 billion, with Zacks Consensus Estimates at $4.97 and $2.87 billion respectively [8]

Core Insights - Revvity (RVTY) reported revenue of $729.37 million for the quarter ended December 2024, reflecting a year-over-year increase of 4.8% [1] - The company's EPS was $1.42, up from $1.25 in the same quarter last year, surpassing the consensus estimate of $1.36 by 4.41% [1] - The revenue fell slightly short of the Zacks Consensus Estimate of $730.06 million, resulting in a surprise of -0.10% [1] Financial Performance Metrics - Organic revenue growth in Life Sciences was 5%, exceeding the average estimate of 2.7% from three analysts [4] - Total organic revenue growth was reported at 6%, compared to the average estimate of 4.1% [4] - Organic revenue growth in Diagnostics was 6%, surpassing the average estimate of 5.5% [4] Sales Performance - Net Sales in Life Sciences reached $336.34 million, slightly below the average estimate of $344.79 million, but still showing a year-over-year increase of 5.2% [4] - Net Sales in Diagnostics amounted to $393.24 million, exceeding the average estimate of $385.63 million, with a year-over-year growth of 4.5% [4] Stock Performance - Revvity's shares have returned +13.3% over the past month, outperforming the Zacks S&P 500 composite's +2.9% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Fourth Quarter 2024 Financial Performance - Adjusted revenue reached $730 million, a 5% year-over-year increase[15] - Organic revenue growth was 6%, with no impact from M&A and a negative 1% impact from foreign exchange[15] - Adjusted operating margin was 30.3%, a 280 basis points increase year-over-year[15] - Adjusted EPS was $1.42, a 14% increase year-over-year[15] - Free cash flow was $151 million for the quarter and $578 million for the full year[15] - Adjusted gross margin was 61.4%, a 120 basis points increase year-over-year[15] Full Year 2024 Financial Performance - Adjusted revenue was $2756 million, flat year-over-year[17] - Organic revenue growth was 1%, with no impact from M&A or foreign exchange[17] - Adjusted operating margin was 28.3%, a 30 basis points increase year-over-year[17] - Adjusted EPS was $4.90, a 6% increase year-over-year[17] - Free cash flow was $578 million, representing 96% of adjusted net income[17] - Adjusted gross margin was 61.3%, a 10 basis points decrease year-over-year[17] 2025 Financial Guidance - Revenue is projected to be between $2.80 billion and $2.85 billion, representing a reported growth of 1.5% to 3.5%[27] - Organic revenue growth is expected to be between 3% and 5%, with a negative 1.5% impact from foreign exchange and no impact from M&A[27]

Financial Data and Key Metrics Changes - The company generated total adjusted revenues of $730 million in Q4 2024, resulting in 6% organic growth, which was above expectations [18] - For the full year, total adjusted revenue was $2.76 billion, with 1% organic growth [19] - Adjusted EPS for Q4 was $1.42, exceeding guidance by $0.04, and for the full year, adjusted EPS was $4.90, representing 5% growth year over year [21][22] Business Line Data and Key Metrics Changes - Life Sciences segment generated $336 million in Q4, up 5% on both a reported and organic basis, but down low single digits for the full year [25] - Diagnostics segment generated $393 million in Q4, up 4% on a reported basis and 6% on an organic basis, with 4% organic growth for the full year [27] - The Life Sciences instruments revenue was down high single digits in Q4 and down low double digits for the full year [25] Market Data and Key Metrics Changes - In Q4, organic revenue growth was 5% in Life Sciences and 6% in Diagnostics, with mid single digits growth in the Americas, low single digits in Europe, and mid single digits in Asia, particularly high single digits in China [23] - For the full year, China experienced low single digit growth in diagnostics and mid teens growth in life sciences, but overall, China declined in the low single digits organically [24] Company Strategy and Development Direction - The company plans to step up strategic internal investments in 2025, expecting organic growth to improve [9][31] - A new Life Sciences Solutions business unit will be established, representing approximately 85% of the Life Sciences segment, reflecting a re-segmentation of the Applied Genomics business [14] - The company aims for adjusted operating margin expansion of 20 to 40 basis points in 2025, despite increased investments [31] Management's Comments on Operating Environment and Future Outlook - Management noted that while demand trends have stabilized, the pace of recovery remains uncertain, leading to a cautious outlook for 2025 [39] - The company expects total organic growth in 2025 to be in the range of 3% to 5%, with balanced growth expected throughout the year [30] - Management expressed optimism about the potential for recovery in the Applied Genomics business as it transitions to the Life Sciences Solutions portfolio [63] Other Important Information - The company repurchased $185 million worth of shares in Q4, bringing total buyback activity for 2024 to $370 million [22] - Free cash flow for Q4 was $151 million, with a full year total of $578 million, equating to 96% conversion of adjusted net income [22] Q&A Session Summary Question: Insights on key end markets and recovery areas - Management acknowledged a path to recovery but emphasized uncertainty in the pace of return to normalcy, with diagnostics and software businesses showing signs of improvement while instrumentation remains a concern [39][40] Question: Guidance for China and stimulus impact - Management expects China to align with company growth averages, with modest stimulus impact anticipated [41][42] Question: Segment outlooks relative to overall guidance - Diagnostics is expected to perform above the company average, while Life Sciences is projected to be in the low single digits [46][47] Question: Expectations for reagents growth - Management indicated that the reagents business is gaining market share and is expected to grow in mid single digits for fiscal 2025 [48][50] Question: Q1 guidance and margin visibility - Management noted that Q1 margins are typically below the full year average, with a similar cadence expected as in 2024 [54] Question: Applied Genomics recovery expectations - Management expressed optimism about the recovery of the Applied Genomics business as it transitions to the Life Sciences Solutions portfolio [63] Question: FX impact on margins - Management clarified that FX does not have a material impact on operating margins [66] Question: Strategic investments for 2025 - Management highlighted increased investments in digital capabilities and expanding sales channels as part of their strategy for 2025 [70]

Company Performance - Revvity (RVTY) reported quarterly earnings of $1.42 per share, exceeding the Zacks Consensus Estimate of $1.36 per share, and up from $1.25 per share a year ago, representing an earnings surprise of 4.41% [1] - The company posted revenues of $729.37 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.10%, but up from $695.9 million year-over-year [2] - Over the last four quarters, Revvity has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Market Performance - Revvity shares have increased approximately 13.7% since the beginning of the year, outperforming the S&P 500's gain of 3.2% [3] - The current consensus EPS estimate for the upcoming quarter is $1.11 on revenues of $678.51 million, and for the current fiscal year, it is $4.97 on revenues of $2.87 billion [7] Industry Outlook - The Medical Services industry, to which Revvity belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Revvity's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Financial Performance - Fourth quarter 2024 GAAP revenue was $729 million, representing a 5% increase year-over-year, with organic growth of 6%[3][4][8] - Fourth quarter 2024 adjusted earnings per share from continuing operations was $1.42, compared to $1.25 in the same period last year[4][8] - Full year 2024 GAAP revenue was $2,755 million, slightly up from $2,751 million in 2023[5][6] - Full year 2024 adjusted earnings per share from continuing operations was $4.90, an increase from $4.65 in 2023[6] - The company reported a net income of $94.6 million for the fourth quarter 2024, compared to $78.6 million in the same period last year[21] - Net income for the three months ended December 29, 2024, was $94,645,000, compared to $78,563,000 for the same period in 2023, representing a year-over-year increase of 20.5%[29] - Income from continuing operations for the twelve months ended December 29, 2024, was $283,071,000, up from $179,503,000 in 2023, reflecting a growth of 57.7%[29] Operating Income and Margins - Fourth quarter 2024 GAAP operating income from continuing operations was $119 million, up from $77 million in the same period last year[3][4] - Full year 2024 GAAP operating profit margin from continuing operations was 12.6%, compared to 10.9% in 2023[5] - Fourth quarter 2024 adjusted operating income was $221 million, compared to $192 million in the same period last year[4] - Reported operating income from continuing operations for the twelve months ended December 29, 2024, was $346,741 thousand, compared to $300,562 thousand for the same period in 2023, an increase of about 15%[24] - Operating margin (OP%) improved to 30.3% in Q4 2024 from 27.5% in Q4 2023[24] Revenue by Segment - Life Sciences segment revenue for Q4 2024 was $336,340 thousand, up from $319,691 thousand in Q4 2023, representing a growth of approximately 5.3%[24] - Diagnostics segment revenue for Q4 2024 was $393,240 thousand, an increase from $376,419 thousand in Q4 2023, reflecting a growth of about 4.5%[24] - The company reported a 5% organic revenue growth in the Life Sciences segment for the three months ended December 29, 2024[31] - The Diagnostics segment achieved an organic revenue growth of 4% for the three months ended December 29, 2024, despite a 1% negative impact from foreign exchange rates[31] Guidance and Future Outlook - The company initiated full year 2025 guidance, forecasting total revenue of $2.80-$2.85 billion and adjusted earnings per share of $4.90-$5.00[11][12] - The company plans to continue focusing on operational efficiency and strategic investments to drive future growth[33] Cash Flow and Assets - The company reported a net cash provided by operating activities of continuing operations of $664,955,000 for the twelve months ended December 29, 2024, compared to $279,387,000 in 2023, indicating a significant increase of 138.4%[29] - Cash, cash equivalents, and restricted cash at the end of the period were $1,164,452,000, an increase from $914,373,000 at the end of the previous year[30] - Total current assets decreased to $2,349,608 thousand in Q4 2024 from $3,001,091 thousand in Q4 2023, a decline of approximately 22%[26] - Cash and cash equivalents increased to $1,163,396 thousand in Q4 2024 from $913,163 thousand in Q4 2023, showing a growth of about 27%[26] - The company experienced a net cash used in financing activities of continuing operations amounting to $1,128,235,000 for the twelve months ended December 29, 2024, compared to $947,121,000 in 2023[30] Non-GAAP Measures - The company uses "adjusted operating income" to refer to GAAP operating income, which includes revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules[40] - "Free cash flow" is defined as net cash provided by operating activities of continuing operations, less capital expenditures, plus proceeds from capital disposals[41] - "Adjusted net income" excludes various costs such as amortization of intangible assets and significant litigation matters, reflecting a more accurate performance of ongoing operations[42] - "Adjusted earnings per share" from continuing operations is calculated by excluding costs related to debt extinguishment and asset impairments, among others[43] - Management excludes amortization of intangible assets from non-GAAP measures as it does not reflect ongoing operational performance[44] - Significant expenses related to acquisitions and divestitures are excluded from non-GAAP measures to provide a clearer view of operational performance[45] - The company does not consider asset impairments and restructuring charges as reflective of ongoing operations, thus excluding them from adjusted measures[46] - Non-GAAP financial measures are not considered superior to GAAP financial statements and should be viewed in conjunction with them[47] - These non-GAAP measures are used by management to evaluate operating performance and benchmark results against peers[48]

Revvity, Inc. (RVTY) is slated to report fourth-quarter 2024 results on Jan. 31, before market open.In the last reported quarter, the company delivered an earnings surprise of 13.27%. RVTY’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.55%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $730.1 million, up 4.9% from the prior-year quarter’s level. The consensus mar ...